National Register of Antipsychotic Medication in Pregnancy
The National Register of Antipsychotic Medication in Pregnancy (NRAMP)
This study is tracking pregnant women who take antipsychotic medications and their babies for a year to see how these medications affect their health and improve care for both.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | The Alfred Academic / other |
| Locations | 1 site (Melbourne, Victoria) |
| Trial ID | NCT00686946 on ClinicalTrials.gov |
What this trial studies
This observational study tracks women of child-bearing age who are taking antipsychotic medications during pregnancy and follows both mother and baby for the first 12 months after birth. The aim is to develop evidence-based guidelines to improve the management of antipsychotic use during pregnancy, thereby enhancing maternal and infant health outcomes. By collecting and analyzing data, the study seeks to inform clinical teams on best practices for treating this vulnerable population. The findings will contribute to better understanding the implications of antipsychotic medication on pregnancy and postpartum health.
Who should consider this trial
Good fit: Ideal candidates for this study are women who are currently taking antipsychotic medication and are either pregnant or have given birth within the last 12 months.
Not a fit: Patients who do not take antipsychotic medication during pregnancy or who are not within the specified time frame post-birth may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved health outcomes for mothers and infants exposed to antipsychotic medications during pregnancy.
How similar studies have performed: While there have been studies on the effects of mental illness during pregnancy, this specific approach of creating a national register for antipsychotic medication use is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women who take antipsychotic medication during pregnancy * Women who are pregnant or have had a baby in the last 12 months * Women who are living in Australia * Women who are able to provide informed consent Exclusion Criteria: * Women who do not take antipsychotic medication during pregnancy * Women who are not pregnant, or have not had a baby in the last 12 months * Women who are unable to provide informed consent
Where this trial is running
Melbourne, Victoria
- Monash Alfred Pyschiatry Research Centre, Alfred Hospital — Melbourne, Victoria, Australia (Recruiting)
Study contacts
- Principal investigator: Prof Jayashri Kulkarni, MBBS,FRANZCP — Monash Alfred Psychiatry Research Centre (MAPrc)
- Study coordinator: Prof Jayashri Kulkarni, MBBS,FRANZCP
- Email: jayashri.kulkarni@med.monash.edu.au
- Phone: 61-3-9076-6564
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.